Cancer in systemic sclerosis

Ami Shah, Masataka Kuwana

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


It has long been recognized that patients with systemic sclerosis (scleroderma) have a higher risk of cancer compared to individuals in the general population. This increased risk could be secondary to damage from the disease process itself, a consequence of the immunosuppressive and cytotoxic therapies used to treat scleroderma, common environmental exposures, or from a shared genetic predisposition to develop both cancer and autoimmunity. Alternatively, it has been hypothesized that cancer therapies, including various chemotherapeutic agents and radiation therapy, may trigger the development of vascular and fibrotic complications characteristic of scleroderma. Recent data demonstrate that a subset of patients have paraneoplastic scleroderma due to the development of antitumor immune responses that may become cross-reactive and result in autoimmunity. In this chapter, we explore these potential links between cancer and scleroderma, discuss a paraneoplastic model of scleroderma pathogenesis, and suggest implications for cancer screening and therapeutics in this patient population.

Original languageEnglish (US)
Title of host publicationScleroderma: From Pathogenesis to Comprehensive Management
PublisherSpringer International Publishing
Number of pages8
ISBN (Electronic)9783319314075
ISBN (Print)9783319314051
StatePublished - Jan 1 2016


  • Cancer
  • Malignancy screening
  • Paraneoplastic
  • Risk factors
  • RNA polymerase III autoantibodies
  • Systemic sclerosis

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Cancer in systemic sclerosis'. Together they form a unique fingerprint.

Cite this